Recent insider trends for ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) have caught the attention of investors. Analysts monitor insider data to understand the sentiment of a company’s largest and most important shareholders. IMUC’s insider trading patterns have some implications for where the stock might be headed.
Institutions own 01.64% of ImmunoCellular Therapeutics, Ltd. (IMUC)’s shares. The total value of these holdings, in millions, is $0. Among active positions in the latest quarter, 5 holders increased their positions by a total of 74168 shares, 4 holders decreased the positions by a total of 142810 shares, and 10 holders held their positions. This works out to a net decrease in ownership of 68642 shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 2 holders initiated new positions by a total of 51663 shares and 3 holders exited their positions by a total of 142748 shares. This nets out to a decrease of 91085 shares and is another bearish sign for IMUC.
Insider ownership increased by a total of 0 shares, which suggests that IMUC’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a different story: insiders executed 1 sells, and ownership decreased by a net of 3284 shares.
Short interest is another tool that analysts use to gauge investor sentiment. It represents the number of a stock’s shares that are being shorted by investors. ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC)’s short interest is 1.72 million shares, or 49.97% of the float. This represents an increase of 23% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
Ownership trends and trading patterns can be useful tools for predicting a stock’s performance, but it’s also important to consider the technicals in order to form a more comprehensive view. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that IMUC is a Weak buy, which implies that IMUC is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) is undervalued.